Johnson & Johnson (NYSE:JNJ) Shares Bought by Sheaff Brock Investment Advisors LLC

Key Points

• Sheaff Brock Investment Advisors LLC increased its holdings in Johnson & Johnson by 143.8% in Q1, owning 44,600 shares valued at approximately $7.4 million.
• Johnson & Johnson reported earnings of $2.77 EPS for the last quarter, exceeding estimates of $2.68, with revenues of $23.74 billion.
• The company announced a quarterly dividend of $1.30 per share, yielding 3.09%, to be paid on September 9th.

Sheaff Brock Investment Advisors LLC grew its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 143.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 44,600 shares of the company's stock after purchasing an additional 26,304 shares during the period. Sheaff Brock Investment Advisors LLC's holdings in Johnson & Johnson were worth $7,396,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of JNJ. GAMMA Investing LLC lifted its stake in shares of Johnson & Johnson by 24,450.4% in the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock valued at $1,196,596,000 after purchasing an additional 7,185,977 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock valued at $3,844,580,000 after buying an additional 4,842,582 shares during the period. Janus Henderson Group PLC raised its holdings in shares of Johnson & Johnson by 134.5% in the 4th quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company's stock valued at $1,149,536,000 after buying an additional 4,559,147 shares during the period. Northern Trust Corp raised its holdings in shares of Johnson & Johnson by 12.3% in the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock valued at $4,456,201,000 after buying an additional 3,363,235 shares during the period. Finally, Pacer Advisors Inc. raised its holdings in shares of Johnson & Johnson by 1,382.0% in the 1st quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company's stock valued at $502,509,000 after buying an additional 2,825,626 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of several research analyst reports. Barclays boosted their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Morgan Stanley boosted their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. UBS Group boosted their price objective on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a report on Thursday, July 17th. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Finally, Raymond James Financial cut their price target on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a report on Monday, April 14th. Nine analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Trading Down 0.7%

NYSE:JNJ opened at $168.29 on Monday. The stock has a market cap of $404.92 billion, a P/E ratio of 18.00, a P/E/G ratio of 2.14 and a beta of 0.41. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The stock has a 50-day simple moving average of $156.08 and a 200-day simple moving average of $155.97.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The business's revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the firm earned $2.82 EPS. As a group, analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.09%. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.